Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02576301 |
Title | Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS |
Acronym | AML |
Recruitment | Unknown status |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | OXiGENE |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
David Geffen School of Medicine at UCLA | RECRUITING | Los Angeles | California | 90095 | United States | Details |
University of Florida | RECRUITING | Gainesville | Florida | 32610 | United States | Details |
University of Miami Sylvester Comprehensive Cancer Center | RECRUITING | Miami | Florida | 33136 | United States | Details |
University of Kansas Cancer Center and Medical Pavilion | RECRUITING | Westwood | Kansas | 66205 | United States | Details |